NIPT was first discovered by Sequenom Inc., in 2010 when they launched the SensiGene Fetal RHD Genotyping laboratory-developed test to detect circulating cff-DNA from maternal blood. NIPT is rapidly commercializing due to the advancement of non-invasive technologies associated with it. The exponential growth of the NIPT market is supported by various factors, such as reimbursement policies, insurance coverage, high incidence rate of Down’s syndrome, no risk of miscarriage with NIPT, and shifting trend toward childbirth at advanced maternal age (35 years or above). However, low cost-effectiveness and inconsistent insurance coverage are hindering the market growth in some parts of the globe, mainly in the developing and under-developed nations of the world. Further, NIPT is also used for fetal sex determination and fetal rhesus D status determination in some parts of Europe. As of 2015, NIPT was offered in 60 countries throughout six continents.

1. Product Definition 

2. Scope of the Work 

3. Research Methodology 

4. Market Overview 

5. Market Dynamics

6. Industry Insights

7. Competitive Landscape 

8. Global NIPT Market (by Test), 2019-2030

9. Global NIPT Market (by Method), 2019-2030 

10. Global NIPT Market (by Platform), 2019-2030 

11. Global NIPT Market (by Application), 2019-2030 

12. Global NIPT Market (by End User), 2019-2030 

13. Global NIPT Market (by Region), 2019-2030

14. Company Profiles